welcome to cyprotex
home > news & events > newsletters

Newsletters

Latest News

Cyprotex will be expanding into newly constructed laboratory space this year.

new labFollowing the completion of new laboratory space at the end of 2008, construction work is now underway for an additional 100 square metres of laboratory space in 2010. We are introducing a range of new products and services. Towards the middle of 2010 we are planning the launch of a brand new range of early in vitro toxicology services. There will be considerable investment in the area of high content screening and this will be a key area of focus for the business later this year. Expansion of our existing ADME services is also important to us - strengthening our breadth of offerings to our customers and enabling the ability to deliver larger, more strategic contracts.

Introducing Cloe® Knowledge.

Cloe KnowledgeOur web portal will continue to grow with the launch of Cloe® Knowledge introducing valuable new features to view and interpret your data. New features will include the ability to upload, collate, store and search your data, compare against data for marketed drugs, predict properties from the data available, and give advice on the most worthwhile assays to screen. More details on Cloe® Knowledge will be posted on Cloe Gateway® as they become available.

https://www.cloegateway.com/services/cloe_knowledge/pages
/service_frontpage.php

April last year marked the 10th year in operation for Cyprotex!

Cyprotex 10Our experience, expertise and reputation have grown considerably over the years, and our success is evident by the retention and significant expansion of our customer base.

contact

Contact us for more information on Cyprotex Discovery, including our extensive range of ADMET/PK services
and pricing.

contact
careerscontactlegalprivacy
This website was last updated
on 31st August 2010
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.